Treatment of Type 2 Diabetes in Chronic Kidney Disease

When type 2 diabetes is accompanied by chronic kidney disease (CKD), glycemic management must also address the risk of progressive kidney function loss and cardiovascular events. Standard glucose-lowering strategies are not sufficient on their own — the selection of therapy is guided by evidence of organ protection, not only glucose control.

Clinical scenario: Adults with type 2 diabetes and confirmed eGFR 20–60 mL/min/1.73 m², and/or albuminuria (albumin-to-creatinine ratio ≥3.0 mg/mmol [30 mg/g]).

In this population, the therapeutic goal extends beyond A1C targets. Treatment choices are selected for their demonstrated ability to slow CKD progression and reduce cardiovascular risk — irrespective of the current A1C level.

Treatment approach (partial): For patients already on a maximally tolerated dose of renin-angiotensin system blockade, the protocol specifies adding a particular class of glucose-lowering agent with primary evidence of reducing CKD progression — one that can be initiated even at significantly reduced kidney function. The complete selection criteria, alternatives, and full algorithm are in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.2337/dc26-S009

In adults with type 2 diabetes who have chronic kidney disease (CKD) (with confirmed estimated glomerular filtration rate [eGFR] 20–60 mL/min/1.73 m² and/or albuminuria), an SGLT2 inhibitor or GLP-1 RA with demonstrated benefit in this population should be used for both glycemic management and for slowing progression of CKD and reduction in cardiovascular events (irrespective of A1C).

SGLT2i can be started with eGFR ≥20 mL/min/1.73 m².

View source ↗